|
Main | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Brand Name | Topamax | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Generic Name | topiramate | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mechanism | Blocks voltage-dependent sodium channels, augments GABA, antagonizes AMPA/kainate subtype of glutamate receptor, inhibits carbonic anhydrase enzyme (isozymes II and IV) MW 339. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Pharmacokinetics | Peak plasma within 2 hours. Relative bioavailability of 80%. PK linear. Plasma elimination half-life is 21 hours. 70% excretion in urine, unmetabolized. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Administration | Oral | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Label | Epilepsy, Migraine | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Clinical Studies | n=487 epilepsy who had 1-2 well-documented seizures during 3-month baseline phase. 400mg vs 50mg KM curve was p=0.0002 in time to first seizure. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2 migraine studies. 26 weeks showed -1.1 for placebo vs -1.2, -2.1 and -2.4 for topamax 50,100 and 200mg. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IP | 8/2008. 30-month stay expected to expire in 9/2006 for MYL. Will someone launch at risk? Cobalt expires 3/08. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Side Effects | Metabolic acidosis, myopia, glaucoma, oligohidrosis, hyperthermia, cognition dysfunction, psychiatric disturbances, somnolence or fatigue | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Efficacy | Responder rates around 40% in 6 epilepsy studies vs 0-20% for placebo. Response rate is % of patients with at least a 50% reduction. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 1Q02 | 2Q | 3Q | 4Q | 1Q03 | 2Q | 3Q | 4Q | 1Q04 | 2Q | 3Q | 4Q | 1Q05 | 2Q | 3Q | 4Q | 1Q06 | 2Q | 3Q | 4Q | 1Q07 | 2Q | 3Q | 4Q | 1Q08 | | | |
| Topamax (8/2008) | 117 | 109 | 143 | 159 | 181 | 205 | 192 | 226 | 254 | 257 | 287 | 293 | 310 | 334 | 327 | 319 | 373 | 393 | 435 | 429 | 501 | 472 | 498 | 535 | 520 | | | |
| International | 32 | 39 | 41 | 47 | 50 | 58 | 60 | 70 | 75 | 78 | 79 | 88 | 96 | 97 | 102 | 94 | 98 | 102 | 98 | 100 | 109 | 106 | 115 | 117 | 126 | | | |
| Worldwide | 149 | 148 | 184 | 206 | 231 | 263 | 252 | 296 | 329 | 335 | 366 | 381 | 406 | 431 | 429 | 413 | 471 | 495 | 533 | 529 | 610 | 578 | 613 | 652 | 646 | 0 | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | | | | | | | | | | | | | |
| Topamax (8/2008) | 358.3 | 528 | 804 | 1091 | 1290 | 1630 | 2006 | 2306.8999999999996 | | | | | | | | | | | | | | | | | | | | |
| International | 119 | 159 | 238 | 320 | 389 | 398 | 447 | 514.05 | | | | | | | | | | | | | | | | | | | | |
| Worldwide | 477.3 | 687 | 1042 | 1411 | 1679 | 2028 | 2453 | 2820.95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| USA | | 0.47362545353056085 | 0.5227272727272727 | 0.35696517412935314 | 0.18240146654445466 | 0.26356589147286824 | 0.23067484662576687 | | 0.33832668417171274 | | | | | | | | | | | | | | | | | | | |
| International | | 0.3361344537815125 | 0.4968553459119496 | 0.34453781512605053 | 0.21562499999999996 | 0.023136246786632286 | 0.12311557788944727 | | 0.2565674065825987 | | | | | | | | | | | | | | | | | | | |
| WW | | 0.4393463230672532 | 0.5167394468704511 | 0.3541266794625719 | 0.18993621545003547 | 0.2078618225134008 | 0.20956607495069024 | | | | | | | | | | | | | | | | | | | | | |